RUNX1 and acute myeloid leukemia: We next employed published ChIP-seq data from primary human AML patient cells (Ptasinska et al, 2014) to assess whether evidence exists for RUNX1 binding to signature 3 genes for which we could demonstrate essential pro-survival functions in the URE-AML model.